Monitoring of clinical trials. Establishment, measures and consequences

被引:0
|
作者
Pritsch, M [1 ]
Unnebrink, K [1 ]
机构
[1] Heidelberg Univ, Abt Med Biometrie, D-69120 Heidelberg, Germany
关键词
clinical trials; monitoring; interim analyses;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clinical trials play an important role in developing and establishing new therapeutic and diagnostic procedures. In the planning and execution of these trials procedures and measures which allow for continual observation, description and evaluation of the study progress are to be taken into account. This is due to ethical, scientific and economic considerations. Together these procedures and measures are termed "monitoring". Repeated evaluation of the main study question is one particular monitoring measure. Results from this sequential procedure may lead to an early termination of patient recruitment. In the last 3 decades methods for interim analyses were developed which take into account the increased chance of errors when evaluating repeatedly the same question. By adjustment they guarantee prespecified level of significance in the end result of the trial. Even though statistical significance may be evident in an interim analysis, this has not always to result in early termination of the trial. The decision to end a trial early must include other considerations than the mere evaluation of the main study question. In particular, consequences of the decision such as credibility and transferability of the trial result to subsequent therapeutic routine application are to be discussed.
引用
收藏
页码:72 / 76
页数:5
相关论文
共 50 条
  • [1] Monitoring of clinical trials. Establishment, measures and consequences
    Pritsch, M
    Unnebrink, K
    [J]. MEDIZINISCHE KLINIK, 1999, 94 (12) : 712 - 717
  • [2] Monitoring klinischer StudienBegründungen, Maßnahmen und KonsequenzenMonitoring of clinical trials. Establishment, measures and consequences
    Maria Pritsch
    Kristina Unnebrink
    [J]. Medizinische Klinik, 1999, 94 : 712 - 717
  • [3] Outcome measures in psoriatic arthritis clinical trials.
    Reddy S.M.
    Bingham Iii C.O.
    [J]. Current Rheumatology Reports, 2005, 7 (4) : 299 - 305
  • [4] Good clinical practices in monitoring antihypertensive clinical trials.
    Jett, CM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 115A - 115A
  • [5] Timing of assessments for PRO measures in advanced RCC clinical trials.
    Agrawal, Sundeep
    Cheng, Joyce
    Bhatnagar, Vishal
    King-Kallimanis, Bellinda
    Pazdur, Richard
    Kluetz, Paul Gustav
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Ancient clinical trials.
    Lewis, EJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01): : 83 - 84
  • [7] Glycitein for clinical trials.
    Verbruggen, MA
    Olieman, K
    [J]. JOURNAL OF NUTRITION, 2002, 132 (03): : 601S - 601S
  • [8] Advancement in KRAS clinical trials.
    Yeung, Wayne
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [9] Clinical trials. A pending subject
    Gil-Extremera, B.
    Jimenez-Lopez, P.
    Mediavilla-Garcia, J. D.
    [J]. REVISTA CLINICA ESPANOLA, 2018, 218 (03): : 137 - 141
  • [10] Use of biomarkers in clinical trials.
    Ransohoff, DF
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2768S - 2768S